Compass Pathways/$CMPS
CMPS jumps after reporting its COMP360 psilocybin treatment met primary endpoints in both Phase 3 trials for treatment-resistant depression.
7 hours ago·Lightyear AI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Compass Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Ticker
$CMPS
Sector
Primary listing
Employees
166
Headquarters
Website
Compass Pathways Metrics
BasicAdvanced
$558M
-
-$2.74
1.94
-
Price and volume
Market cap
$558M
Beta
1.94
52-week high
$8.20
52-week low
$2.25
Average daily volume
1.4M
Financial strength
Current ratio
1.228
Quick ratio
1.146
Long term debt to equity
54.71
Total debt to equity
93.597
Interest coverage (TTM)
-34.27%
Profitability
EBITDA (TTM)
-154.377
Effective tax rate (TTM)
-0.54%
Management effectiveness
Return on assets (TTM)
-38.43%
Return on equity (TTM)
-205.81%
Valuation
Price to book
14.84
Price to tangible book (TTM)
14.84
Price to free cash flow (TTM)
-3.125
Free cash flow yield (TTM)
-32.00%
Free cash flow per share (TTM)
-1.859
Growth
Earnings per share change (TTM)
24.70%
3-year earnings per share growth (CAGR)
10.27%
What the Analysts think about Compass Pathways
Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.
Compass Pathways Financial Performance
Revenues and expenses
Compass Pathways Earnings Performance
Company profitability
Compass Pathways News
AllArticlesVideos
Compass Pathways Launches Proposed $150.0 Million Public Offering
Business Wire·2 hours ago
Compass Pathways' depression treatment meets main goal in late‑stage study
Reuters·11 hours ago
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Business Wire·11 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Compass Pathways stock?
Compass Pathways (CMPS) has a market cap of $558M as of February 17, 2026.
What is the P/E ratio for Compass Pathways stock?
The price to earnings (P/E) ratio for Compass Pathways (CMPS) stock is 0 as of February 17, 2026.
Does Compass Pathways stock pay dividends?
No, Compass Pathways (CMPS) stock does not pay dividends to its shareholders as of February 17, 2026.
When is the next Compass Pathways dividend payment date?
Compass Pathways (CMPS) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Pathways?
Compass Pathways (CMPS) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.